| Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149, 2017 | 436 | 2017 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120, 2019 | 311 | 2019 |
| Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study BA Teply, H Wang, B Luber, R Sullivan, I Rifkind, A Bruns, A Spitz, ... The Lancet Oncology 19 (1), 76-86, 2018 | 182 | 2018 |
| Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide ES Antonarakis, C Lu, B Luber, C Liang, H Wang, Y Chen, JL Silberstein, ... European urology 74 (2), 218-225, 2018 | 173 | 2018 |
| Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer K Boudadi, DL Suzman, V Anagnostou, W Fu, B Luber, H Wang, ... Oncotarget 9 (47), 28561, 2018 | 144 | 2018 |
| Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication J Theruvath, M Menard, BAH Smith, MH Linde, GL Coles, GN Dalton, ... Nature medicine 28 (2), 333-344, 2022 | 127 | 2022 |
| Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer P Isaacsson Velho, JL Silberstein, MC Markowski, J Luo, TL Lotan, ... The Prostate 78 (5), 401-407, 2018 | 122 | 2018 |
| Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer Y Zhu, A Sharp, CM Anderson, JL Silberstein, M Taylor, C Lu, P Zhao, ... European urology 73 (5), 727-735, 2018 | 64 | 2018 |
| Clinical utility of CLIA-grade AR-V7 testing in patients with metastatic castration-resistant prostate cancer MC Markowski, JL Silberstein, JR Eshleman, MA Eisenberger, J Luo, ... JCO precision oncology 1, 1-9, 2017 | 62 | 2017 |
| Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer S Torquato, A Pallavajjala, A Goldstein, P Valda Toro, JL Silberstein, ... JCO precision oncology 3, 1-14, 2019 | 55 | 2019 |
| Analytical validation of androgen receptor splice variant 7 detection in a clinical laboratory improvement amendments (CLIA) laboratory setting PM Lokhandwala, SL Riel, L Haley, C Lu, Y Chen, J Silberstein, Y Zhu, ... The Journal of Molecular Diagnostics 19 (1), 115-125, 2017 | 49 | 2017 |
| Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells S Maddineni, JL Silberstein, JB Sunwoo Journal for Immunotherapy of Cancer 10 (5), 2022 | 40 | 2022 |
| An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA N Mehta, S Maddineni, RL Kelly, RB Lee, SA Hunter, JL Silberstein, ... Scientific reports 10 (1), 15171, 2020 | 38 | 2020 |
| Novel insights into molecular indicators of response and resistance to modern androgen-axis therapies in prostate cancer JL Silberstein, MN Taylor, ES Antonarakis Current urology reports 17, 1-10, 2016 | 32 | 2016 |
| Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). K Boudadi, DL Suzman, B Luber, H Wang, J Silberstein, R Sullivan, ... Journal of Clinical Oncology 35 (15_suppl), 5035-5035, 2017 | 31 | 2017 |
| Detection fidelity of AR mutations in plasma derived cell-free DNA A Goldstein, PV Toro, J Lee, JL Silberstein, M Nakazawa, I Waters, ... Oncotarget 8 (9), 15651, 2017 | 26 | 2017 |
| AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort. ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 34 (15_suppl), 5012-5012, 2016 | 24 | 2016 |
| CD52 is elevated on B cells of SLE patients and regulates B cell function K Bhamidipati, JL Silberstein, Y Chaichian, MC Baker, TV Lanz, A Zia, ... Frontiers in immunology 11, 626820, 2021 | 17 | 2021 |
| The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 36 (15_suppl), 5004-5004, 2018 | 16 | 2018 |
| Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone … J Silberstein, B Luber, H Wang, C Lu, Y Chen, Y Zhu, MN Taylor, ... Journal of Clinical Oncology 35 (6_suppl), 132-132, 2017 | 6 | 2017 |
